Compare BioNTech SE - ADR (BNTX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs TORM plc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while TORM plc trades at $29.7 (market cap $3.02B). The key difference: BioNTech SE - ADR is far larger — about 7.6× TORM plc's market cap, and TORM plc pays a 9.52% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TRMD | |
|---|---|---|
Market Cap | $22.86B | $3.02B |
Sector | Health | Technology |
52-Week High | $119.34 | $34.87 |
52-Week Low | $83.89 | $17.46 |
Enterprise Value | $6.53B | $3.90B |
Dividend Yield | — | 9.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
TRMD trades at $28.86, down 2.1% today, with a bullish technical signal supported by moving averages despite neutral oscillators. The company shows strong fundamentals with a P/E of 8.62, net income margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, highlighting strong freight market conditions and operational execution.
Outlook remains positive with 100% analyst buy ratings and attractive valuation metrics. Key opportunities include the upcoming Q2 2026 earnings report and consistent dividend payments. Risks include earnings volatility, geopolitical impacts on shipping rates, and competitive pressures in the tanker market that could affect future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
